JO Ebbert, MV Burke, JT Hays, RD Hurt - Nicotine & Tobacco Research, 2009 - ntr.oxfordjournals.org Results: Demographic characteristics were similar between the two groups. Among
smokers receiving varenicline and NRT, 71% used the nicotine patch with a mean
dose of 32 mg/day (SD = 14) and 73% used at least two types of NRT. Adverse ... Cited by 2 - Related articles - All 3 versions
VP Quinn, JF Hollis, KS Smith, NA Rigotti, LI … - Journal of General Internal Medicine, 2009 - Springer Page 1. ORIGINAL ARTICLES Effectiveness of the 5-As Tobacco Cessation Treatments
in Nine HMOs Virginia P. Quinn, PhD 1 , Jack F. Hollis ... Cited by 3 - Related articles - All 2 versions
- ►nih.gov JB McClure, GE Swan, L Jack, SL Catz, SM … - Journal of general internal medicine, 2009 - Springer Page 1. Mood, Side-effects and Smoking Outcomes Among Persons With and Without
Probable Lifetime Depression Taking Varenicline Jennifer ... Cited by 4 - Related articles - All 5 versions
JO Ebbert, LC Dale, H Severson, IT … - Nicotine & tobacco research, 2007 - ntr.oxfordjournals.org Nicotine lozenges have been shown to increase tobacco abstinence rates in
cigarette smokers, but they have not been evaluated in smokeless tobacco (ST)
users. We conducted an open-label, one-arm, phase II clinical trial to ... Cited by 6 - Related articles - BL Direct - All 6 versions
[CITATION] Mental Health Services Administration, Office of Applied Studies. Results from the 2007 …
JO Ebbert, IT Croghan, A Sood, DR Schroeder … - Nicotine & Tobacco Research, 2009 - ntr.oxfordjournals.org Methods: We enrolled cigarettes smokers in an open-label, one-arm, Phase II
clinical trial to obtain preliminary data on the potential effectiveness and
safety of combination therapy with varenicline and bupropion SR for the ... Cited by 7 - Related articles - All 3 versions
MK Ho, JC Mwenifumbo, N Al Koudsi, KS … - Clinical Pharmacology & Therapeutics, 2009 - nature.com Cytochrome P450 2A6 (CYP2A6) is the main nicotine (NIC)-metabolizing enzyme in
humans. We investigated the relationships between CYP2A6 genotype, baseline
plasma trans- 3'-hydroxycotinine/cotinine (3HC/COT) (a phenotypic marker of ... Cited by 5 - Related articles - All 3 versions
JR Hughes - Journal of Smoking Cessation, 2007 - Aus Acad Press The Need for Tobacco Treatment Specialists Currently, at least two types of
behavioural therapies and seven medications reliably help smokers to stop
smoking (Aveyard & West, 2007). What organisations should deliver these ... Cited by 5 - Related articles - All 3 versions
MB Steinberg, S Greenhaus, AC Schmelzer, … - Ann Intern Med, 2009 - utmem.edu Background: Smokers with medical illnesses are at particular risk for
complications caused by tobacco. Clinical trial data on the effec- tiveness of
triple-combination pharmacotherapy for tobacco depen- dence treatment in ... Cited by 6 - Related articles - View as HTML - All 11 versions
- ►nih.gov LC Dale, JO Ebbert, ED Glover, IT Croghan, … - Drug and alcohol dependence, 2007 - Elsevier The 7-day point-prevalence tobacco abstinence rates did not differ between
bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio
(OR) 1.3; p = 0.301). The 7-day point-prevalence abstinence did not differ ... Cited by 9 - Related articles - All 17 versions
